Welcome to our dedicated page for Novavax SEC filings (Ticker: NVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Novavax, Inc. (NASDAQ: NVAX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Novavax is a vaccine-focused biotechnology company that reports on its financial condition, material agreements, capital structure and key product and partnership developments through forms such as 10-K, 10-Q and 8-K.
Current Reports on Form 8-K for Novavax frequently address material events tied to its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, the Matrix-M® adjuvant platform and major collaborations. Examples include disclosures about the collaboration and license agreement with Sanofi, marketing authorization transfers for Nuvaxovid in the European Union and United States that trigger milestone payments, amendments expanding Sanofi’s license to use Matrix-M in pandemic influenza vaccine candidates, and milestone payments and royalties associated with partners such as Takeda. Other 8-K filings describe site consolidation transactions in Maryland, non-cash impairment charges, and convertible senior note exchanges and issuances that shape the company’s capital structure.
Periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide detail on Novavax’s revenue components, including product sales, supply sales and licensing, royalties and other revenue, as well as research and development and selling, general and administrative expenses. They also expand on risk factors related to regulatory approvals, manufacturing, partnerships and market adoption of its vaccines.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly see key points from lengthy 10-K and 10-Q reports, understand the impact of 8-K announcements on partnerships and financing, and review information about potential equity issuance and debt obligations, including convertible senior notes. The filings page also surfaces insider and executive-related filings, such as Forms 3, 4 and 5, when available, to help track equity ownership changes.
All documents are updated in near real time as they are posted to the SEC’s EDGAR system, allowing investors and researchers to review Novavax’s official disclosures, assess how collaboration agreements and regulatory decisions affect the business, and follow the evolution of its vaccine and adjuvant platform through formal reporting.
Novavax EVP and Chief Legal Officer Mark J. Casey reported equity compensation activity involving restricted stock units and common stock. On March 3, 2026, 4,000 restricted stock units were converted and 37,500 shares of common stock were acquired through an exercise or conversion of derivative securities at a stated price of
In a related move, 11,378 shares of common stock were withheld at
Novavax EVP of R&D Ruxandra Draghia-Akli reported new equity awards and related share movements. On March 2, 2026, she received 93,000 Restricted Stock Units and a non-statutory stock option for 139,500 shares at $9.09 per share, each vesting over several years subject to continued employment.
On March 3, 2026, 26,667 RSUs were converted into common stock, with the same number of RSUs disposed back to the company. To cover tax withholding on RSU vesting, 11,313 shares of common stock at $9.49 per share were withheld, leaving her with 23,563 common shares held directly.
Novavax, Inc. President and CEO John C. Jacobs reported multiple equity transactions. On March 2, 2026, he received a grant of 367,500 Restricted Stock Units and a grant of 551,500 Non-Statutory Stock Options with an exercise price of
On March 1, 2026, 83,333 Restricted Stock Units were exercised into 83,333 shares of common stock at
Novavax Inc. executive Kelly James Patrick, EVP, CFO and Treasurer, reported multiple equity compensation transactions. On
On
Novavax EVP and Chief Strategy Officer Elaine O'Hara reported a series of equity-related transactions. She received a grant of 118,000 Restricted Stock Units (RSUs) and a stock option for 177,500 shares at an exercise price of
On the same dates, previously granted RSUs for 19,600 and 40,000 units were exercised into common stock. To satisfy tax withholding obligations tied to these vestings, 5,375 and 10,969 shares of common stock were disposed of at
Novavax EVP and Chief Legal Officer Mark J. Casey reported several equity transactions. On March 2, 2026, he received a grant of 101,000 restricted stock units and a non-statutory stock option for 152,000 shares at $9.09 per share, both vesting over multiple years subject to continued employment.
On March 1, 2026, 4,000 restricted stock units were exercised into 4,000 shares of common stock, and 1,214 shares were withheld at $10.14 per share to cover tax obligations. Following these transactions, he continued to hold directly owned common stock and derivative awards tied to Novavax shares.
Novavax reported a sharp turnaround in 2025, moving to net income of $440 million from a $187 million loss in 2024, driven by partnerships and cost cuts. Total revenue rose to $1.12 billion, up 65% from $682 million, with $625 million from Nuvaxovid product sales, largely tied to prior Advance Purchase Agreement settlements.
Fourth quarter 2025 revenue was $147 million, up 67% from $88 million, and net income was $18 million versus a loss of $81 million a year earlier. Licensing, royalties and other revenue reached $438 million in 2025, including $386 million from Sanofi, where Novavax earned $225 million in milestones for the year.
The company highlighted a new Matrix-M license agreement with Pfizer, including a $30 million upfront payment and up to $500 million in milestones plus high-mid-single digit royalties, and continued progress under its Sanofi collaboration. Cash and marketable securities totaled $751 million at year end, and Novavax added a $330 million credit facility with an initial $50 million draw.
Novavax exceeded its 2025 R&D and SG&A reduction goals, cutting full-year SG&A to $157 million from $337 million and R&D to $342 million from $391 million. For 2026, it guides to Adjusted Total Revenue of $230–$270 million and Non-GAAP combined R&D and SG&A expenses of $310–$340 million as it shifts to a partnership-led model.
Novavax, Inc. filed its annual report describing a vaccine-focused business built on its protein-based nanoparticle platform and Matrix-M™ adjuvant, used in its Nuvaxovid COVID‑19 vaccine and the R21/Matrix‑M malaria vaccine. The company emphasizes partnerships and a lean operating model to fund ongoing R&D.
Key commercial moves include a global collaboration with Sanofi, which triggered a $175 million milestone upon FDA approval of Nuvaxovid’s BLA and will eventually shift COVID‑19 commercialization to Sanofi, plus future milestone and royalty potential on COVID‑19, COVID‑influenza combination, and other adjuvanted products. Novavax also signed a non‑exclusive Matrix‑M license with Pfizer including a $30 million upfront payment and up to $500 million in milestones, and amended its agreement with Takeda in Japan to a royalty-based structure.
The company continues to unwind legacy COVID‑19 supply contracts. It recognized $575.7 million of product sales after Canada terminated its APA, while refunding $28.0 million, and recorded $27.3 million of product sales following a settlement with New Zealand. Remaining advance purchase obligations total about $0.4 billion, including $133.9 million with Australia and $225.0 million with Gavi, with portions potentially refundable if regulatory or supply conditions are not met. As of June 30, 2025, non‑affiliate equity market value was approximately $1.018 billion, and there were 162,935,945 shares outstanding as of February 16, 2026.
Bank of America Corporation has disclosed beneficial ownership of 8,315,530 shares of Novavax, Inc. common stock, representing 5.1% of the outstanding class as of the date used in the calculation. Most shares carry shared voting and dispositive power, with no sole authority reported.
The filing states these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Novavax. The position is held across Bank of America and wholly owned subsidiaries, including broker-dealer and banking entities.
State Street Corporation reports beneficial ownership of 9,523,646 shares of Novavax, Inc. common stock, representing 5.9% of the class as of 12/31/2025. All voting and dispositive authority is described as shared, with no sole power reported.
The filing lists several affiliated asset management subsidiaries, including SSGA Funds Management and State Street Global Advisors entities, as the investment managers involved. State Street certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Novavax.